Dyax, Serono enter agreement for antibody discovery

By Lisa Kerner

Charlotte, N.C., Sept. 7 - Dyax Corp. granted Serono SA a non-exclusive license to its proprietary antibody phage display libraries.

Serono will use the libraries to discover and develop therapeutic antibodies.

Under the agreement, Serono will pay Dyax technology license fees and employee payments for the funded research, clinical milestone payments and royalties on net sales of any resulting products.

In addition to Serono, Dyax leverages its technology through collaborations with Amgen, Biogen-Idec, Genzyme Corp., ICOS Corp., ImClone Systems Inc. and MedImmune Inc.

Dyax is a pharmaceutical company based in Cambridge, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.